The use of stable-isotopically labeled substrates and analysis by mass spectrometry has provided substantial insight into rates of synthesis, disposition and utilization of lipids in vivo. The information to be gained from such studies is of particular benefit to therapeutic research where the underlying causes of disease may be related to the production and utilization of lipids. When studying biology through the use of isotope tracers, care must be exercised in interpreting the data to ensure that any response observed can truly be interpreted as biological and not as an artifact of the experimental design or a dilutional effect on the isotope. In this manuscript, we have studied the effects of dosing route and tracer concentration on the mass isotopomer distribution profile as well as the action of selective inhibitors of microsomal triglyceride transfer protein (MTP) in mice and diacylglycerol acyltransferase 1 (DGAT1) in non human primates using a stable-isotopically labeled approach. Subjects were treated with inhibitor and subsequently given a dose of uniformly 13 C-labeled oleic acid. Samples were analyzed using a rapid LC-MS technique, allowing the effects of the intervention on the assembly and disposition of triglycerides, cholesteryl esters and phospholipids to be determined in a single 3 minute run from just 10 μL of plasma.
Introduction
Understanding the synthesis and disposition of triglycerides, cholesteryl esters and phospholipids is an important component in developing effective therapies to treat cardiovascular and metabolic disease. The kinetics of synthesis and disposition can be ascertained by introducing a labeled substrate and measuring its incorporation into, and decay from, bulk lipid pools which provides useful information on the flux of lipid through the relevant synthetic and metabolizing pathways. Such techniques have been used to study the kinetics of synthesis of VLDL triglycerides (1-3), cholesterol (4, 5) and phospholipids (6) as well as many other aspects of lipid disposition. When introducing a labeled substrate into a biological system the pattern of labeling in downstream metabolites conveys information about the synthesis of the product. By experimentally measuring this labeling pattern and comparing the results to those predicted by combinatorial probability, it is possible to determine kinetic parameters. This technique has been termed mass isotopomer distribution analysis (MIDA); discussions on consideration for use and the limits of applicability of the method have been presented (7, 8) . A central tenet of MIDA is that differences in the observed concentration of a particular isotopomeric product can be due solely to the relative abundances of the labeled precursor and the endogenous form of the substrate, i.e. the labeling of the precursor pool. In effect, introduction of the label represents an intervention on the system and this carries important ramifications for interpreting observed effects when a second intervention, e.g. dosing of a pharmacological agent, is carried out in tandem with dosing of the labeled substrate. Observed differences in the synthesis of a particular mass isotopomer could be due to isotope dilution, effects of the pharmacological agent, or both. Thus, when using a stable-isotopically labeled tracer approach to evaluate the effects of drugs in vivo, it behooves the researcher to assess the labeling of the precursor pool (to evaluate comparability among subjects and between treated and control groups) in order to determine whether an observed effect can truly be attributed to action of the drug (9, 10) .
When stable-isotopically labeled substrates are utilized to interrogate metabolite synthesis in biological systems, analysis of the samples is often accomplished using GC-MS analysis (11) . This technique generally requires that complex molecules with high boiling points, such as triglycerides, phospholipids and cholesteryl esters, first be separated from one another using off-line methods such as thin layer chromatography and secondly be saponified and derivatized so that analysis can be carried out on an appropriate molecular component (e.g. labeled fatty acid or glycerol). In contrast to GC-MS based approaches, LC-MS requires less sample pre-processing and enables the analysis of intact molecular lipids. The ability of LC-MS to separate different classes of lipids, such as triglycerides, phosphatidylcholines and cholesteryl esters, in a single run is another significant advantage and allows the disposition of the tracer between different lipid pools to be easily explored. A recent publication by Qi and colleagues (12) describes the utility of an LC-MS based approach to monitoring the effects of pharmacological inhibitors of DGAT1 on di-and triglyceride assembly from stableisotopically labeled oleic acid in vitro and in vivo. Although the authors demonstrated the capability of the LC-MS method to measure multiple labeled forms of di-and triglyceride simultaneously, little detail on the mass isotopomer distribution profile was presented and no analysis of precursor pool labeling was described. 
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In this manuscript, we present data from a series of 5 experiments in which administration of uniformly 13 C labeled oleic acid has been used to elucidate lipid assembly in vivo, using a rapid LC-MS method to measure the labeling pattern of triglycerides, phospholipids and cholesteryl esters. Initial experiments explored the effects of route of administration and dose of the isotope on the labeling pattern of various triglycerides. By administering high doses of the labeled oleate we demonstrate that it is possible to steer lipid synthesis in vivo towards defined mass isotopomers and also show that a single isotopomer can be representative of the total pool, allowing bulk behaviour to be inferred from the analysis of a single biomarker. Subsequent experiments, using selective inhibitors of MTP in mice and DGAT1 in non human primates, highlight the utility of this approach to assess perturbations in lipid assembly resulting from pharmacological intervention. Comparability between treated and control groups in labeling of the precursor pool is demonstrated for each experiment, allowing the true pharmacological effects to be clearly interpreted. Similarity in the mass isotopomer distribution profile between two preclinical species, mouse and non human primate, has been explored for oral dosing and highlights the utility of the stable isotope method for translational studies in pharmaceutical research.
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Materials and Methods
Animal Studies.
All animals were maintained in ALAAC accredited facilities. 
Selective Inhibitors of MTP and DGAT1.
To explore the effects of pharmacological perturbation on the disposition of the tracer fatty acid, selective inhibitors of microsomal triglyceride transfer protein and diacylglycerol acyltransferase 1 were synthesized. The specific inhibitors used in these investigations were selected from molecules disclosed in the scientific or patent literature (13-15).
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Determination of Precursor Labeling
Labeling of the precursor (oleate) pool was calculated based on the ratio of the M 2 /M 1 isotopomers of plasma triglycerides following exposure to the 13 C 18 oleic acid tracer. The precursor labeling (p) was calculated using the equation (22):
Statistical Analysis.
Statistical analyses of data were performed by unpaired, two-tailed Student's t-test or ANOVA using the GraphPad Prism software package (GraphPad Software, La Jolla, CA).
Data are presented as mean ± SEM and p values <0.05 were considered significant.
GraphPad was also used to determine areas under the plasma timecourse curve (AUC).
Results
LC-MS method development and identification of lipid markers
The predominant TG and phosphatidylcholine (PC) molecular species in mouse plasma were initially identified by neutral loss scanning for oleate (m/z 299.2) or precursor scanning for the choline headgroup (m/z 184.3), respectively. Figure 1 shows an example of the chromatographic separation obtained as well as the extracted mass spectra.
The most intense species were identified initially by m/z. Authentic standards were injected and matched to peaks in biological samples on the basis of retention time; further characterization by accurate mass Q-TOF MS/MS was carried out to confirm the fatty acid compositions reported in In this case, the precursor pool effectively consists of the 13 C 18 -oleic acid tracer and whatever lipid can be derived from intracellular stores or the systemic circulation.
Experiment 2: Intravenous Administration of Isotope: Effect of Different Vehicles.
Hepatic lipid synthesis draws from different precursor pools than intestinal lipid synthesis.
Fatty acid substrates can be derived from chylomicron remnants, synthesized de novo in the hepatocyte or taken up from the systemic circulation after lipolysis of adipose triglyceride. Depending on nutritional state, systemically derived NEFA can be the dominant contributor (1) . Hepatic assembly of lipids can thus be probed by administering a fatty acid tracer intravenously to form part of the plasma NEFA pool. 
Experiment 3: Effect of a DGAT1 Inhibitor on Distribution of isotope Given as an Oral Bolus
To investigate the effects of pharmacological perturbation on lipid synthesis in the intestine, african green monkeys were treated with ascending doses of a selective DGAT1
inhibitor. One hour following compound administration, animals were given an oral dose (50 mg/kg body weight) of 13 C 18 -oleic acid formulated in 20% TPGS and blood was collected at serial timepoints to measure tracer incorporation into circulating triglycerides. Figure 3 shows the effects of the DGAT1 inhibitor on incorporation of the labeled oleic acid into the different mass isotopomers of triolein (TG 54:3) as well as the precursor pool labelling over the timecourse for each dosed group as determined by LC-MS. As observed in the formulation experiments conducted in mice, the M3 isotopomer was found to predominate over lesser labeled forms. This led us to investigate whether the effect of the DGAT1 compound on assembly of this single isotopomer could be shown to be representative of oleate incorporation into the total pool of circulating triglyceride. To achieve this, the triglyceride fraction from aliquots of the same plasma samples were isolated by TLC and saponified. Total triglyceride bound 13 C 18 -oleic acid was determined by GC-MS. conditions that .incorporation of isotope into a single molecular species of triglyceride can be representative of the behaviour of the bulk pool.
Experiment 4: Effect of an MTP Inhibitor on Distribution of isotope Given as an IV Bolus
To investigate the effects of pharmacological perturbation on lipid synthesis in the liver, C57Bl/6 mice were pseudo-fasted and treated with a single dose (50 mg/kg body weight)
of an MTP inhibitor. One hour after compound administration mice were injected with 50 mg/kg body weight of the 13 C 18 -oleic acid via tail vein and blood was collected at serial timepoints afterward. Previous data in mice administered a 50 mg/kg intravenous dose of the isotope showed substantial incorporation into the M 3 isotopomer of triolein (Table 3 ). Figure 5 shows the effects of the MTP inhibitor on appearance of the M 3 isotopomer of triolein in plasma, as well as on the M 1 isotopomer of PC 34:1. The enrichment of the oleate precursor pool measured over the timecourse is reported in Table 4 . The data collected 30 minutes after administration of the isotope agrees very well with data from Experiment 2. More importantly, the enrichment of the oleate precursor pool was found be highly comparable between the vehicle and compound treated groups giving confidence that the inhibition of isotope incorporation into triglyceride evidenced in Figure 5 can be unambiguously attributed to the action of the MTP inhibitor. determined. From this information, quantitative information on the labeling of the precursor pool can be derived through simple calculations (22). In order to confidently determine that differences in the assembly/synthesis of newly made lipid are due to a pharmacological perturbation, it is important to document whether the labeling of the precursor pool is equivalent between treated and control subjects. Providing this burden is met, it can be safely concluded that differences in the appearance of labeled lipids are truly due to the effects of the treatment and not to differences in isotope (precursor) dilution. The data contained in Figures 3 and 4 illustrate the utility of LC-MS to evaluate the impact of pharmacological intervention while providing a means for assessing labeling of the precursor pool. These figures also illustrate the additional information that can be derived from evaluating the mass isotopomer distribution profile and how this can help to further understanding of the underlying biology.
Consider the triglyceride excursion curves shown in Figure 3 for african green monkeys treated with a DGAT1 inhibitor and orally exposed to the tracer fatty acid dosed in TPGS. demonstrates that the precursor pool labeling was equivalent between the control and DGAT1 compound-treated groups over the course of the experiment, providing confidence that the decreased incorporation of the tracer into newly synthesized TG is truly due to inhibition of the enzyme. The finding that the M 3 isotopomer is the dominant version of triolein formed is comparable to the data presented in Table 2 for the mouse by guest, on October 22, 2017
www.jlr.org Downloaded from study, illustrating an important concept for pharmaceutical development. The fact that similar isotopomer distribution profiles were observed for both mice and non-human primates for labeled oleate dosed orally in TPGS illustrates that methods developed in one preclinical model have the potential to be translatable to higher species. This is a substantial benefit of the stable-isotopically labeled tracer approach but does rely on a complete analysis of the isotopomer profile to understand similarities and potential differences between species.
The data shown in Figure 3 
Conclusions
The use of LC-MS to follow the disposition of stable-isotopically labeled oleic acid in vivo provides all the tools required to interrogate biology and confidently assess pharmacological effects. Analysis of the mass isotopomer distribution profile at the same time as the efficacy of the drug is being assessed provides an empirical means to document labeling of the precursor pool, an important consideration when using these techniques for therapeutic research. By using an appropriate experimental design, we have also shown that it is possible to infer bulk behaviour from the analysis of a single biomarker. This allows analysts to develop targeted methods requiring small sample volumes and short run times, enabling rapid assessment of pharmacological effects and facilitating quick decision making. Although these are all significant advantages, it is important to draw attention to the limitations of the experiment. For the investigations presented here, we selected oleate as the tracer fatty acid based on findings that it serves as a reliable probe for lipid synthesis (35) and on our own evaluations of the suitability of this substrate for the systems under study. Table 1 and were confirmed by accurate mass MS/MS on a Waters Q-TOF (Synapt G2). 
